Journal of Medicinal and Aromatic Plant Sciences

Volume: 44 Issue: 3

  • subscription
  • Original Research Article

Molecular docking and dynamics simulation studies on sakuranetin a phytomolecule targeting AChE receptor against Alzheimer’s disease

HASAN, I., KHAN, S., SINGH, P., PRAKASH, O. M., KHAN, F.*

Technology Dissemination & Computational Biology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.-CIMAP,
Lucknow-226015, India.

*Corresponding Author, E-mail: [email protected]

Year: 2022, Page: 97-105, Doi: https://doi.org/10.62029/jmaps.v44i3.Hasan

Received: Dec. 11, 2022 Accepted: Dec. 25, 2022 Published: Dec. 30, 2022

Abstract

Alzheimer’s disease (AD) is a common type of dementia, mainly characterized by neurodegeneration and memory loss with other cognitive impairments in the brain. AD is one of the fastest emerging irrecoverable diseases in the aging population. Moreover, the degeneration of central cholinergic neurons damages memory and leads to cholinergic dysfunction. Several natural phytomolecules and semisynthetic analogs have been used to treat AD for years. However, no preventive treatment is available to date because most of the available drugs/compounds have failed in clinical trials. AChE is one of the most promising therapeutic targets for symptomatic improvement in AD patients. The current study was done to screen several natural phytomolecules derived from the Verbenaceae family's Lippia graveolens (Mexican Oregano). Based on the in silico results, Sakuranetin was the best potential AChE antagonist (-8.24 kcal/mol), and the primary amino acid residues, i.e., Tyr124, Tyr341, Leu289, and Phe295, were involved in the active binding site of AChE. The compound has shown a good fit and can cross the blood–brain barrier (BBB) along with high levels of intestinal absorption. Furthermore, Sakuranetin and AChE complex was found to be stable as analyzed by 10 ns molecular dynamics simulations. Based on the free binding energy and stability, it may be concluded that Sakuranetin is a potential hit compound for treating Alzheimer’s disease.
 

Keywords: Alzheimer disease, Molecular Docking, Molecular dynamics simulation, Neurotransmitters, Sakuranetin

References

Abraham, M., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multilevel parallelism from laptops to supercomputers. SoftwareX, 1, 19–25.

Bales, K. R., Tzavara, E. T., Wu, S., Wade, M. R., Bymaster, F. P., Paul, S. M., & Nomikos, G. G. (2006). Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody. Journal of Clinical Investigation, 116(3), 825–832.

Bautista-Hernández, I., Aguilar, C. N., Martínez-Ávila, G. C. G., Torres-León, C., Ilina, A., Flores-Gallegos, A. C., Verma, D. K., & Chávez-González, M. L. (2021). Mexican oregano (Lippia graveolens Kunth) as source of bioactive compounds: A review. Molecules, 26, 5156.

Cui, H., Zhang, C., Li, C., & Lin, L. (2019). Antibacterial mechanism of oregano essential oil. Industrial Crops and Products, 139, 111498.

González-Trujano, M. E., Hernández-Sánchez, L. Y., Muñoz-Ocotero, V., Dorazco-González, A., Guevara-Fefer, P., & Aguirre-Hernández, E. (2017). Pharmacological evaluation of the anxiolytic-like effects of Lippia graveolens and bioactive compounds. Pharmaceutical Biology, 55(1), 1569–1576.

Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013). Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology, 80(19), 1778–1783.

Han, J. Y., Besser, L. M., Xiong, C., Kukull, W. A., & Morris, J. C. (2019). Cholinesterase inhibitors may not benefit mild cognitive impairment and mild Alzheimer disease dementia. Alzheimer Disease and Associated Disorders, 33(2), 87–94.

Horak, M., Holubova, K., Nepovimova, E., Krusek, J., Kaniakova, M., Korabecny, J., Vyklicky, L., Kuca, K., Stuchlik, A., Ricny, J., Vales, K., & Soukup, O. (2017). The pharmacology of tacrine at N-methyl-D-aspartate receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 75, 54–62.

Jan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I. (2017). Perspective insights into disease progression, diagnostics, and therapeutic approaches in Alzheimer’s disease: A judicious update. Frontiers in Aging Neuroscience, 9, 356.

Pilau, M. R., Alves, S. H., Weiblen, R., Arenhart, S., Cueto, A. P., & Lovato, L. T. (2011). Antiviral activity of the Lippia graveolens (Mexican oregano) essential oil and its main compound carvacrol against human and animal viruses. Brazilian Journal of Microbiology, 42, 1616–1624.

Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190.

Pascual, M. E., Slowing, K., Carretero, E., Sánchez-Mata, D., & Villar, A. (2001). Lippia: traditional uses, chemistry and pharmacology: A review. Journal of Ethnopharmacology, 76, 201–214.

Perry, E., Walker, M., Grace, J., & Perry, R. (1999). Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends in Neurosciences, 22(6), 273–280.

Prathap, L., Jayaraman, S., Roy, A., Santhakumar, P., & Jeevitha, M. (2021). Molecular docking analysis of stachydrine and sakuranetin with IL-6 and TNF-α in the context of inflammation. Bioinformation, 17(3), 363–368.

Li, C., Hu, C., Wang, R., Wang, H., Ma, Q., Chen, S., & He, Y. (2019). Protective effect of sakuranetin in brain cells of dementia model rats. Cellular and Molecular Biology (Noisy-le-Grand), 65(1), 54–58.

Liang, Z., & Maher, P. (2022). Structural requirements for the neuroprotective and anti-inflammatory activities of the flavanone sterubin. Antioxidants, 11(11), 2197.

Lin, L. Z., Mukhopadhyay, S., Robbins, R. J., & Harnly, J. M. (2007). Identification and quantification of flavonoids of Mexican oregano (Lippia graveolens) by LC-DAD-ESI/MS analysis. Journal of Food Composition and Analysis, 20(5), 361–369.

Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010). Alzheimer’s disease: Clinical trials and drug development. The Lancet Neurology, 9(7), 702–716.

Spitzer, N. C. (2012). Activity-dependent neurotransmitter respecification. Nature Reviews Neuroscience, 3(2), 94–106.

McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & CV, M. (2017). Recent advances in acetylcholinesterase inhibitors and reactivators: An update on the patent literature (2012–2015). Expert Opinion on Therapeutic Patents, 27(4), 455–476.

Summers, W. K. (2006). Tacrine and Alzheimer’s treatments. Journal of Alzheimer’s Disease, 9(4), 439–445.

Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018). Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. International Journal of Molecular Sciences, 19(6), 1578.

Torre de la, M. P., Cavero, R. Y., & Calvo, M. I. (2022). Anticholinesterase activity of selected medicinal plants from Navarra region of Spain and a detailed phytochemical investigation of Origanum vulgare L. ssp. vulgare. Molecules, 27, 7100.

Torres-León, C., Ventura-Sobrevilla, J., Serna-Cock, L., Ascacio-Valdés, J. A., Contreras-Esquivel, J. C., & Aguilar, C. N. (2017). Pentagalloylglucose (PGG): A valuable phenolic compound with functional properties. Journal of Functional Foods, 37, 176–189.

Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.

Turek, C., & Stintzing, F. C. (2013). Stability of essential oils: A review. Comprehensive Reviews in Food Science and Food Safety, 12(1), 40–53.

Rao, R. V., Descamps, O., John, V., & Bredesen, D. E. (2012). Ayurvedic medicinal plants for Alzheimer’s disease: A review. Alzheimer’s Research & Therapy, 4, 22.

Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & Mackerell, A. D., Jr. (2010). CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry, 31(4), 671–690.

Weller, J., & Budson, A. (2018). Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research, 31, 1161.

Cite this article

Hasan, I., Khan, S., Singh, P., Prakash, O. M., & Khan, F. (2022). Molecular docking and dynamics simulation studies on sakuranetin a phytomolecule targeting AChE receptor against Alzheimer’s disease. Journal of Medicinal and Aromatic Plant Sciences, 44(3), 97–105.

Views
1062
Downloads
1
Citations